Autologous Mesenchymal Stem Cells in Spinal Cord Injury (SCI) Patients (MSC-SCI)

Clínica Las Condes. LIT INNOVA CORFO

Status and phase: Unknown; Phase 2

Conditions: Spinal Cord Injury

Treatments: Procedure: Autologous Mesenchymal Stem Cells

Study type: Interventional

Funder types: Other

Identifiers

NCT01694927

LIT-2012-ACF-001

Details and patient eligibility

About

The aim of this study is to evaluate the use of autologous expanded mesenchymal stem cells intralesional transplantation as a safe and potentially beneficial treatment for patients with spinal cord injury.

Enrollment: 30 estimated patients

Sex: All

Ages: 2 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• American Spinal Injury Association Impairment (ASIA) Scale A, B and C
• Cervical (under C4), thoracic o lumbar spine lesion
• Complete or Incomplete SCI
• Platelet count over 100.000/ul

Exclusion criteria

• Acute SCI (less than 3 months)
• Active infectious diseases
• Pregnancy
• Neurodegenerative diseases
• Primary hematologic diseases
• Coagulopathies
• Hepatic dysfunction
• Pregnancy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

Mesenchymal Stem cells

Experimental group

Treatment:

Procedure: Autologous Mesenchymal Stem Cells